Monoclonal antibodies have been recognised for their significant potential in the treatment of multiple myeloma. At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Christof Scheid, MD, PhD, from University of Cologne, Cologne, Germany, reviews the clinical development of elotuzumab, which targets CS1, and daratumumab, which targets CD38.